Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
Jake Robert ThompsonJulia Lai-KwonRachael Lisa MortonAlexander D GuminskiMaria GonzalezVictoria AtkinsonShahneen SandhuMichael P BrownAlexander M MenziesGrant A McArthurSerigne N LôGeorgina V LongIris BartulaPublished in: Immunotherapy (2023)
Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab-nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan-Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab-nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab-nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration : NCT02374242 (ClinicalTrials.gov).
Keyphrases
- clinical trial
- brain metastases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- white matter
- resting state
- multiple sclerosis
- randomized controlled trial
- cross sectional
- open label
- ejection fraction
- papillary thyroid
- peritoneal dialysis
- depressive symptoms
- machine learning
- brain injury
- combination therapy
- prognostic factors
- patient reported outcomes
- lymph node metastasis
- big data
- sleep quality
- replacement therapy